

## Needleless Injection, DME 26

### Table of Content

[Description & Definitions](#)[Criteria](#)[Document History](#)[Coding](#)[Special Notes](#)[References](#)[Keywords](#)

<u>Effective Date</u>	10/2000
-----------------------	---------

<u>Next Review Date</u>	01/2026
-------------------------	---------

<u>Coverage Policy</u>	DME 26
------------------------	--------

<u>Version</u>	9
----------------	---

**Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details <sup>\*</sup>.**

### Description & Definitions:

Needleless Injection deliver medications either without a needle stick, the use of a tiny jet stream, or a single pulse of laser light and disposable devices are worn for short periods of time to decrease repeated punctures to the skin.

### Criteria:

Needleless injection systems are considered medically necessary with **1 or more** of the following:

- Documentation includes **All** of the following:
  - Documented evidence that individual is unable to perform insulin injection/standard blood glucose monitoring with a traditional delivery device after adequate training and is unable to use the traditional device
  - Documented evidence of “sharps phobia” such as repeated episodes of vasovagal reaction to injection or standard blood glucose monitoring making puncture technique impossible
  - Documentation of contact with diabetes educator for training to ensure proper technique and instruction has been offered to individual using traditional device
- Individuals with **All** of the following:
  - Predisposed to prolonged hyperinsulinemia and subsequent hypoglycemia
  - Demonstrate better glycemic control with the jet injector compared with conventional needle and syringe
- Individuals who are predisposed to lipoatrophy since jet injections may be less likely to lead to this complication compared with needle injection
- Individuals with gestational diabetes who experience postprandial hyperglycemia with needle injection since it may reduce the risk of neonatal macrosomia

The following **do not meet the definition of medical necessity**, to include but not limited to:

- Insuflon
- Laser lancet devices

## Document History:

### Revised Dates:

- 2025: No change to criteria. Updated to new policy format.
- 2024: January
- 2023: January
- 2021: January, May
- 2019: November
- 2011: June
- 2009: June
- 2008: June, August
- 2007: September
- 2006: October
- 2003: October
- 2002: October

### Reviewed Dates:

- 2022: January
- 2021: August
- 2020: September
- 2019: April
- 2018: August
- 2017: November
- 2016: June
- 2015: June
- 2014: June
- 2013: June
- 2012: June
- 2010: June
- 2009: August
- 2006: December
- 2005: December
- 2004: October, December

### Effective Date:

- October 2000

## Coding:

Medically necessary with criteria:

Coding	Description
A4210	Needle-free injection device, each
E1399	Durable medical equipment, miscellaneous

Considered Not Medically Necessary:

Coding	Description
A4257	Replacement lens shield cartridge for use with laser skin piercing device, each
E0620	Skin piercing device for collection of capillary blood, laser, each

*The preceding codes are included above for informational purposes only and may not be all inclusive. Additionally, inclusion or exclusion of a treatment, procedure, or device-code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.*

## Special Notes: \*

- Coverage: See the appropriate benefit document for specific coverage determination. Individual specific benefits take precedence over medical policy.
- Application to products: Policy is applicable to Sentara Health Plan Commercial products.
- Authorization requirements: Pre-certification by the Plan is required.
- Special Notes:
  - Commercial
    - Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.
    - Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

## References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Code of Federal Regulations. Title 29 Subtitle B Chapter XVII Part 1910 Subpart Z § 1910.1030. 1.1.2025. Retrieved 1.3.2025. <https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XVII/part-1910/subpart-Z/section-1910.1030>

Office of Combination Products Office of Special Medical Programs Office of the Commissioner Food and Drug Administration. Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products. 6.2013. Retrieved 1.3.2025. <https://www.fda.gov/media/76403/download>

Hayes. A symplr Company. Health Technology Assessment. Jan 10,2014. Needle-Free Insulin Injection Systems. Retrieved 1.3.2025. <https://evidence.hayesinc.com/report/dir.needle105>

Centers for Medicare and Medicaid Services. CMS.gov. NCD Insulin Syringe (40.4) Version 1. No date. Retrieved 1.3.2025. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=133>

Centers for Medicare and Medicaid Services. CMS.gov. NCD Home Blood Glucose Monitors (40.2) Version 2. 6.19.2006. Retrieved 1.3.2025. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=222>

Centers for Medicare and Medicaid Services. CMS.gov. LCD Glucose Monitors (L33822) Revision 16. 10.1.2024. Retrieved 1.3.2025. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lclid=33822>

Department of Medical Assistance Services. DMAS.gov. Procedure Fee Files & CPT Codes. 2025. <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

National Comprehensive Cancer Network. NCCN.org. Retrieved 1.3.2025. <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=needleless%20devices>

American Diabetes Association. Needle-Free Jet Injection of Rapid-Acting Insulin Improves Early Postprandial Glucose Control in Patients With Diabetes. 10.2013. Retrieved 1.3.2025. <https://doi.org/10.2337/dc13-0492>

Sanghi, D.K., Tiwle, R. INTERNATIONAL JOURNAL OF PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL SCIENCES. AN UPDATE: ON NEEDLE FREE INJECTIONS. 2023. Retrieved 1.3.2025. <https://www.ijpcbs.com/articles/an-update-on-needle-free-injections.pdf>

Phatale, V., Vaiphei, K. K., Jha, S., Patil, D., Agrawal, M., & Alexander, A. (2022). Overcoming skin barriers through advanced transdermal drug delivery approaches. Journal of controlled release : official journal of the Controlled Release Society, 351, 361–380. Retrieved 1.3.2025. <https://doi.org/10.1016/j.jconrel.2022.09.025>

MCG Informed Care Strategies. 28<sup>th</sup> Edition. 2024. Retrieved 1.3.2024. <https://careweb.careguidelines.com/ed28/index.html>

## Keywords:

SHP Needleless Injection and Lancet Devices, SHP DME 26, Needleless, lancet, iport, injector, sharps phobia, diabetes, insuflon, hyperinsulinemia, subsequent hypoglycemia, needle, syringe, needle-free injectors, Jet injector, Bi-3m Needle-Free Injector System, Pharmajet Needle-Free Injector, Stratis Injector, Hypex(Tm) Jet Injector, Med-E-Jet Injector, Injet-100, Medajet XI, Vitajet II, AdvantaJet, Freedom Jet, Medi-Jector EZ, Biojector 2000, Comfort-In injector system